BrainStorm Cell Therapeutics (BCLI): EV/EBITDA Multiple
Brainstorm Cell (BCLI) is implementing automated bioreactors to develop drugs for nerve cell degeneration, eliminating manual labor. The financial foundation relies on the results of clinical trials for ALS therapy, as the company lacks a steady stream of income. A powerful scientific staff is retained through a stock option system and the strategic hiring of top managers. This chart of stock quotes on GURU.Markets confirms these data, and the EV/EBITDA metric stands at .
Analytical breakdowns for brainstorm-cell.com (BCLI)
- current price and projected stock value:
- stock exchange capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Brainstorm Cell|BCLI - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity BrainStorm Cell Therapeutics|BCLI - Company Cumulative Debt|Debt to Book Capitalization Ratio BrainStorm Cell Therapeutics Inc.|BCLI - Company Long-Term Loans and Borrowings|Company Short-Term Debt BrainStorm Cell Therapeutics|Quick Liquidity Indicator brainstorm-cell.com
- business earnings and investment ratios data:
BCLI - Final Profit|Projected Future Earnings Brainstorm Cell|BCLI - Price to Earnings Ratio|Forward P/E Multiple Brainstorm Cell|BCLI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BrainStorm Cell Therapeutics Inc.|BCLI - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months BrainStorm Cell Therapeutics|BCLI - Earnings per share for the last twelve months|Quarterly EPS earnings growth brainstorm-cell.com|BCLI - Earnings per share growth in current year|Earnings growth forecast for next year Brainstorm Cell
Initial company analysis:BCLI (Brainstorm Cell Therapeutics, Inc.)
The EV/EBITDA multiple compares the total enterprise value of a business, including net debt, with its operating profit before interest, taxes, depreciation, and amortization. A decline in this ratio typically signals that an asset is undervalued, whereas a sharp increase warns of the risk of overpayment. The price action of the EV/EBITDA multiple for Brainstorm Cell (BCLI) allows for an assessment of the capitalization of development costs for the NurOwn platform within the context of creating a unique cell therapy ecosystem.
Key competitors
EV/EBITDA Multiple BIIB (Biogen Corp)|EV/EBITDA Multiple Neurocrine Corp NBIX|Regencell Bioscience - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation XENE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Supernus Corp (SUPN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|Enterprise Value to Operating Income Before Depreciation Ratio DNLI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|Biohaven Ltd (BHVN) - Company Value to EBITDA|AMLX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio anavex.com|Enterprise Value to EBITDA Ratio CBLL|PRTA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALEC|Enterprise Value to EBITDA Ratio Annexon Biosciences Inc. ANNX|EV/EBITDA Multiple OMER (Omeros)|neurogene.com (NGNE) - Company Value to EBITDA|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VYGR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SCLX (Scilex Holding Company, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACOG|EV/EBITDA Multiple CGTX|Enterprise Value to EBITDA Ratio Inhibikase Therapeutics Inc IKT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|Assertio Holdings - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Coya - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Vistagen Therapeutics VTGN|ovidrx.com (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ABOS|CRVO (CervoMed Inc) - EV/EBITDA Multiple|Company Value to EBITDA Alterity Therapeutics Ltd ATHE|Enterprise Value to EBITDA Ratio CLNN (Clene Inc.)|EV/EBITDA Multiple pepgen.com (PEPG)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Business Value to Operating Income Before Depreciation RLMD|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Grace Therapeutics, Inc.|AIFF: EV/EBITDA Multiple|KLTO (Klotho Neurosciences) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|RVPH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MTVA|EV/EBITDA Multiple NeurAxis Inc (NRXS)|EV/EBITDA Multiple HSDT (Helius Medical Technologies)|Total Company Value to Operating Income Before Depreciation Ratio Passage Bio Inc. (PASG)|NEUP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NERV (Minerva Neurosciences Inc) - Enterprise Value to Operating Income Before Depreciation|Athira (ATHA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADXN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio ALZN|CYCN (Cyclerion) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|KTTA - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cortigent CRGT|Business Value to Operating Income Before Depreciation ATXI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|chromocell.com (CHRO) - Enterprise Value to EBITDA Ratio|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Marinus Pharma (MRNS)|EV/EBITDA Multiple NKGN|NRBO - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|Synaptogenix Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIGL: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WENA: EV/EBITDA Multiple|CERE (cerevel.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
